Stephen G Dilly MBBS, PhD
Stephen G. Dilly, MBBS, PhD, is Aimmune’s Chief Executive Officer and a member of Aimmune’s Board of Directors. He was formerly the CEO at APT Pharmaceuticals. Dr. Dilly was previously Senior Vice President, Head of Development, and Chief Medical Officer at Chiron BioPharmaceuticals. Before that, he held a number of senior executive clinical, development and commercial support positions at companies including SmithKline Beecham and Genentech.
Dr. Dilly played important roles in the development and approval of numerous drugs, including Kytril®, Requip®, Kredex®, Paxil CR®, Cathflo Activase®, Raptiva®, Xolair®, Avastin®, Lucentis®, Cubicin® and Tarceva®. He is on the Board of Sangamo Biosciences. Dr. Dilly received a PhD in Cardiac Physiology from the University of London and holds an MBBS, graduating as a physician from the University of London.